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Introduction
Calciphylaxis, also called calciﬁc uraemic arteriolo-
pathy, is a rare disease characterized by medial calci-
ﬁcation of the small arteries and ischaemia of
the subcutaneous tissue, often leading to necrosis of
subcutaneous fat and skin. It affects mainly women
with chronic renal insufﬁciency and/or obesity.
According to recent studies, calciphylaxis seems to
occur more frequently than previously believed, with
an incidence of 1% per year [1] and a prevalence of 4%
in dialysis patients [2].
The pathogenesis of calciphylaxis is poorly under-
stood and its treatment is largely empirical and
somewhat controversial. Recent studies have empha-
sized the crucial role of a multidisciplinary therapeutic
approach focusing on the correction of the underly-
ing abnormalities of the calcium and phosphorus
plasma concentrations (using non-calcium-containing
phosphate binders), local wound care with debride-
ment of necrotic tissues and aggressive treatment of
infectious complications [3]. The utility of parathy-
roidectomy, corticoid therapy and hyperbaric oxygen
therapy remains controversial. However, despite inten-
sive combined treatments, the prognosis of calciphy-
laxis remains poor: the overall 1 year survival is 45%
and the 5 year survival is 35%, with a relative risk of
death of 8.5 compared with other dialysis patients [4].
Bisphosphonates have a powerful inhibitory effect
on osteoclast activity and bone resorption and are
largely used in the treatment of osteoporosis, tumoral
hypercalcaemia and Paget’s disease. Some previous
studies have shown that bisphosphonates also have
beneﬁcial effects on the evolution of experimental
calciphylaxis [5,6] and tumoral calcinosis with systemic
inﬂammatory response [7]. According to these latter
observations, we decided to treat a woman with chronic
renal failure and rapidly worsening calciphylaxis with
pamidronate. This treatment brought a spectacular
and rapid improvement of the patient’s clinical con-
dition and a rapid decrease of the inﬂammatory
syndrome. We report this case, which is, to our
knowledge, the ﬁrst one in which a bisphosphonate
has been used to treat a patient with calciphylaxis.
Case
A 59-year-old obese woman (body mass index:
40.1 kg/m2) with a long history of type 2 diabetes and
progressive chronic renal insufﬁciency was hospital-
ized in our hospital in May 2003 for uraemic peri-
carditis and extremely severe pain in the legs. The leg
pain began several months prior to the hospitaliza-
tion and increased progressively to such a point
that it prevented walking and no longer responded to
simple analgesic therapy. On admission, the patient’s
medication further included L-thyroxin 0.1mg/day,
furosemide 80mg/day, epoetin-b 10 000UI/week, insu-
lin 12UI/day and benazepril 5mg/day. On clinical
examination, we recorded a diminished general con-
dition and generalized oedema. Body temperature was
37.3C and blood pressure was 180/100mmHg. There
was a pericardial friction rub on cardiac auscultation.
Examination of the legs showed several erythematous
lesions of the skin and an induration of both calves and
of the medial aspect of the thighs, which was exquisitely
painful on palpation. Three 2–3 cm diameter necrotic
ulcers with purpuric border were noted on the calves.
The peripheral pulses were palpable and there was no
sign of peripheral neuropathy. Laboratory results
included glucose 6.6mmol/l, urea 35.2mmol/l, serum
creatinine 628 mmol/l, sodium 138mmol/l, potassium
6.3mmol/l, ionized calcium 0.94mmol/l, phosphate
2.85mmol/l, intact parathyroid hormone 226 ng/l,
albumin 28.7 g/l, C-reactive protein (CRP) 156mg/l,
haemoglobin 81 g/l, leukocytes 7.3G/l, platelets 282G/l
and creatinine clearance 4ml/min. Echocardiography
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showed a small pericardial effusion and Doppler
ultrasound of the legs ruled out a deep vein thrombosis.
The initial therapy consisted of intensive daily haemo-
dialysis for 10 days, followed by 4 h dialysis three times
a week (with a calcium dialysate of 2.5mEq/l),
antibiotic treatment for suspicion of skin infection
[amoxycillin/clavulanic acid (Augmentin)] and opi-
ates for pain control. At the end of the ﬁrst
hospitalization week, we performed a plain X-ray of
the thighs, which showed extensive vascular calciﬁca-
tion of large and small arteries. A skin biopsy showed
necrotizing panniculitis with medial calciﬁcation of
small arteries, typical of calciphylaxis. In the following
2 weeks, despite normalization of the calcium–
phosphate product, local wound care and antibiotics,
the clinical condition continued to worsen, with exacer-
bation of pain and increase of CRP up to 368mg/l.
At that time we decided to start an intravenous
pamidronate therapy (ﬁve 30mg doses of Aredia at
days 23, 25, 29, 30 and 48 of hospitalization) without
any other concomitant change in the therapy. The
treatment was well tolerated and as soon as 48 h after
the ﬁrst dose of pamidronate, the clinical condition
began to improve: the CRP values decreased rapidly to
20mg/l (Figure 1) and the pain in the legs resolved
simultaneously, allowing us to stop the therapy with
opiates. The three ulcers healed within 1 month and
the patient was discharged 5 weeks after the ﬁrst
pamidronate dose.
Six weeks after discharge, the patient noted a
recurrence of pain in the legs (‘the same pain as when
calciphylaxis began’ said the patient). Again, after an
additional 30mg dose of pamidronate, the symptoms
disappeared in a few days. Thereafter, the patient
remained totally pain-free, there was no recurrence
of the skin lesions and the CRP remained stable
at 20mg/l. A control X-ray of the calves made 6
months later showed no change in the degree of
the vascular calciﬁcations.
Discussion
Calciphylaxis is a painful symmetrical necrotizing
panniculitis associated with medial calciﬁcation of
small- and medium-sized arteries. According to the
distribution of the lesions, we distinguish two forms
of the disease: in the distal form lesions are limited
to the calves and the forearms, while in the proximal
form they also affect the thighs and the abdominal
wall. A proximal distribution of the lesions and the
presence of skin ulcers are associated with a very
poor prognosis [1]. In the proximal form the survival
rate is 23% (vs 63% in the distal form) [1] and if
skin ulcerations develop it is only 11% (vs 79% in
the non-ulcerating form) [8], the main cause of the
high mortality being infection [4].
In the present case of biopsy-proven proximal
ulcerating calciphylaxis, the most striking point was
the rapid and spectacular improvement of the disease
after pamidronate therapy. At the time calciphylaxis
was progressing rapidly in our patient, with worsen-
ing of the clinical condition, exacerbation of pain
and rapid increase of CRP despite dialysis with
low-calcium dialysate, aggressive wound care and
antibiotic therapy for 3 weeks. At that moment we
decided to start pamidronate therapy and we ourselves
were quite surprised to see that as soon as 48 h after
the ﬁrst dose of the drug was administered, the
dramatic course of the disease suddenly changed.
The clinical condition of the patient began to
improve and the pain improved rapidly as well as the
inﬂammatory syndrome. Thereafter, the ulcers healed
also very rapidly, within only 4 weeks. This rapid
change in the course of the disease occurred without
any other concomitant change in therapy or in the
dialysis prescription and strongly suggests a powerful
effect of pamidronate.
To our knowledge, this is ﬁrst report of the use of
a bisphosphonate in the treatment of a patient with
0
50
100
150
200
250
300
350
400
450
0 10 20 30 40 50 60 70
Days after admission
C
R
P
 (
m
g/
l)
Amoxicillin/Clavulanate
Pamidronate 30 mg x 5 doses
Fig. 1. Evolution of the CRP since admission. Each vertical arrow represents a single dose of 30mg pamidronate. Antibiotic therapy was also
given during the ﬁrst 4 weeks of hospitalization (horizontal arrow).
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calciphylaxis. Why did we consider pamidronate? Two
arguments were the basis of our decision. First, two
studies in animals have shown that bisphosphonates
can effectively prevent experimental calciphylaxis
[5,6]. Of course, there are several differences between
these animal models of calciphylaxis and the human
disease, but in both studies the bisphosphonates
were quite effective in preventing the necrotic lesions
associated with the disease. Second, a recent paper [7]
reported the successful treatment of a case of tumoral
calcinosis associated with pyrexia and systemic inﬂam-
matory response for which the prescription of pamid-
ronate (three doses of 30mg) induced the disparition
of fever within a few days and a normalization of the
CRP within 2 weeks. In this latter case, the authors
decided to use pamidronate with the hypothesis that
the inﬂammatory syndrome might result from the
local activity of osteoclasts and an associated release
of proinﬂammatory cytokines. Actually, the inﬂamma-
tory syndrome resolved rapidly but the calciﬁed lesions
remained unchanged, favouring the hypothesis of an
anti-inﬂammatory effect of pamidronate [7]. In our case
also, pamidronate induced rapid resolution of the
inﬂammatory syndrome and of the local symptoms,
while the follow-up X-ray of the legs did not show
any signiﬁcant change in vessel calciﬁcations. This
suggests that the mobilization of calcium salts from
the arterial wall was not an important factor in the
clinical improvement. Several studies have shown
that, apart from their effect on bone, the bisphospho-
nates exert an inhibitory effect on macrophage
activity and local proinﬂammatory cytokine produc-
tion [9,10]. It is our impression that these cellular
effects may have played an important role in the
rapid improvement of our patient (i.e. rapid pain relief,
rapid improvement of CRP and rapid healing of
the necrotic ulcers). One may question whether
other drugs with anti-inﬂammatory properties, such
as steroids, might be useful. Fine and Zacharias [8]
reported that steroids may be beneﬁcial in some
patients with non-ulcerating calciphylaxis, but at the
present time most authors do not recommend their use.
In conclusion, the pathogenesis of calciphylaxis
remains poorly understood and its treatment largely
empirical. At the present time, the treatment is based
mainly on a multidisciplinary therapeutic approach
focusing on the correction of the abnormalities of
calcium–phosphate metabolism, intensive wound care
and aggressive treatment of infection. According to
the present case, bisphosphonates may be an effective
new alternative for the treatment of calciphylaxis.
Of course, further studies are needed to conﬁrm their
efﬁcacy in the treatment of patients with different
types of calciphylaxis.
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